CeriBell (NASDAQ:CBLL) Hits New 52-Week Low – Time to Sell?

CeriBell (NASDAQ:CBLL) hit a new 52-week low during trading on Monday . The company traded as low as $20.06 and last traded at $20.13, with a volume of 13957 shares trading hands. The stock had previously closed at $20.93.

Analysts Set New Price Targets

A number of research analysts recently commented on CBLL shares. Canaccord Genuity Group started coverage on CeriBell in a research note on Tuesday, November 5th. They issued a “buy” rating and a $30.00 target price for the company. William Blair started coverage on CeriBell in a research report on Tuesday, November 5th. They issued an “outperform” rating on the stock. Canaccord Genuity Group upped their price target on CeriBell from $31.00 to $33.00 and gave the company a “buy” rating in a research report on Monday, December 9th. Bank of America started coverage on CeriBell in a research report on Tuesday, November 5th. They issued a “buy” rating and a $32.00 price target on the stock. Finally, JPMorgan Chase & Co. started coverage on CeriBell in a research report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price target on the stock. Six research analysts have rated the stock with a buy rating, According to MarketBeat, CeriBell presently has a consensus rating of “Buy” and a consensus price target of $32.60.

CeriBell Stock Down 3.8 %

The company has a fifty day simple moving average of $27.05.

CeriBell (NASDAQ:CBLL) last announced its earnings results on Tuesday, November 12th. The company reported ($1.85) EPS for the quarter, missing the consensus estimate of ($0.82) by ($1.03). The firm had revenue of $17.20 million during the quarter, compared to the consensus estimate of $17.06 million. On average, equities analysts forecast that CeriBell will post -2.46 earnings per share for the current fiscal year.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.